Neurology

Reader response: New onset refractory status epilepticus research: What is on the horizon?



I read with interest the Contemporary Issues article by Gofton et al.1 on new-onset refractory status epilepticus (NORSE).Treatment for patients with NORSE includes traditional anticonvulsant therapy and intravenous anesthetic for status epilepticus. In addition, many patients are administered with immunotherapies, such as IV methylprednisolone, IV immunoglobulin, plasma exchange, rituximab, or cyclophosphamide. Autoantibodies-induced cases of NORSE may respond to immunogenic therapy, but—at the onset of NORSE—many of these autoantibodies are not readily detectable, and it may take weeks for the results to come back. Do the authors have any recommendation on which patients with NORSE should be immediately treated with immune modulators? In addition, are there any data for treatment of NORSE with allopregnanolone?

Source link






Related posts

Spotlight on the August 6 issue

Newsemia

Science Daily: Watching neurons in action

Newsemia

Serotonin Neurons Contribute to Fail Safe Mechanism that Ensures Recovery From Interrupted Breathing

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy